Selective inhibition of acetyl-lysine effector domains of the bromodomain family in oncology

Cancer Drug Discovery and Development

Volumn 88, Issue , 2014, Pages 279-298

  Müller, Susanne ^a   Lingard, Hannah ^a   Knapp, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ATAD2; BET; BRD NUT; BRG1; Bromodomain; Chromatin; Epigenetic reader modules; Protein acetylation; TIF1alpha; Transcription

Indexed keywords

LYSINE ACETYLSALICYLATE; ROMIDEPSIN; VORINOSTAT;

ARTICLE; CHROMOSOME ABERRATION; EPIGENETICS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOLOGY; PHYLOGENETIC TREE; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS;

EID: 84893035110     PISSN: 21969906     EISSN: 21969914     Source Type: Book Series    
DOI: 10.1007/978-1-4614-8039-6_11     Document Type: Article

References (113)

1. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942):834-840, Epub 2009/07/18.
2. Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6(6):579-589, Epub 2012/09/12.
3. Parra M, Verdin E (2010) Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol 10(4):454-460, Epub 2010/05/08.
4. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M et al (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38(5):566-569, Epub 2006/04/28.
5. Lee JH, Choy ML, Marks PA (2012) Mechanisms of resistance to histone deacetylase inhibitors. Adv Cancer Res 116:39-86, Epub 2012/10/24.
6. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C (2011) The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol 206:13-37, Epub 2011/09/01.
7. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP et al (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391(6667):601-605, Epub 1998/02/19.
8. Buurman R, Gurlevik E, Schaffer V, Eilers M, Sandbothe M, Kreipe H et al (2012) Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143(3):811-820, e1-15. Epub 2012/05/30.
9. Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90(1):85-94, Epub 2011/11/30.
10. Licciardi PV, Ververis K, Tang ML, El-Osta A, Karagiannis TC (2012) Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med 13(4):640-647, Epub 2012/10/16.
11. Marmorstein R, Trievel RC (2009) Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta 1789(1):58-68, Epub 2008/08/30.
12. Yang X, Yu W, Shi L, Sun L, Liang J, Yi X et al (2011) HAT4, a Golgi apparatus-anchored B-type histone acetyltransferase, acetylates free histone H4 and facilitates chromatin assembly. Mol Cell 44(1):39-50, Epub 2011/10/11.
13. Avvakumov N, Cote J (2007) The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26(37):5395-5407, Epub 2007/08/19.
14. Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19(6):1176-1179, Epub 2000/03/16.
15. Tohyama S, Tomura A, Ikeda N, Hatano M, Odanaka J, Kubota Y et al (2012) Discovery and characterization of NK13650s, naturally occurring p300-selective histone acetyltransferase inhibitors. J Org Chem 77(20):9044-9052, Epub 2012/09/19.
16. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D et al (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1):214-231, Epub 2012/04/03.
17. Haynes SR, Dollard C, Winston F, Beck S, Trowsdale J, Dawid IB (1992) The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. Nucleic Acids Res 20(10):2603, Epub 1992/05/25.
18. Muller S, Filippakopoulos P, Knapp S (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13:e29, Epub 2011/09/22.
19. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM et al (2012) Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res 22(12):2315-2327, Epub 2012/10/04.
20. Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX et al (2010) ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 70(22):9402-9412, Epub 2010/09/25.
21. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW (2007) ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA 104(46):18067-18072, Epub 2007/11/14.
22. Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC et al (2012) Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate 73(5):455-466, Epub 2012/10/06.
23. Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P et al (2012) A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res 18(20):5606- 5616, Epub 2012/08/24.
24. Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP (2010) ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ 52(9):747-755, Epub 2010/12/17.
25. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW (2010) Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol 30(22):5260-5272, Epub 2010/09/22.
26. Hennig EE, Mikula M, Rubel T, Dadlez M, Ostrowski J (2012) Comparative kinome analysis to identify putative colon tumor biomarkers. J Mol Med (Berl) 90(4):447-456, Epub 2011/11/19.
27. Panagopoulos I, Strombeck B, Isaksson M, Heldrup J, Olofsson T, Johansson B (2006) Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol 133(3):270-275, Epub 2006/04/29.
28. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA et al (2009) Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23(1):134-143, Epub 2008/11/21.
29. Viejo-Borbolla A, Ottinger M, Bruning E, Burger A, Konig R, Kati E et al (2005) Brd2/ RING3 interacts with a chromatin-binding domain in the Kaposi's Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1. J Virol 79(21):13618-13629, Epub 2005/10/18.
30. Zhou M, Peng C, Nie XM, Zhang BC, Zhu SG, Yu Y et al (2003) Expression of BRD7- interacting proteins, BRD2 and BRD3, in nasopharyngeal carcinoma tissues. Chin J Cancer 22(2):123-127.
31. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME et al (2008) BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27(15):2237-2242, Epub 2007/10/16.
32. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529-533, Epub 2011/10/04.
33. French CA (2012) Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 7:247-265, Epub 2011/10/25.
34. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-917, Epub 2011/09/06.
35. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 109(47):19408-19413, Epub 2012/11/07.
36. You J, Srinivasan V, Denis GV, Harrington WJ Jr, Ballestas ME, Kaye KM et al (2006) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J Virol 80(18):8909-8919, Epub 2006/08/31.
37. Grunwald C, Koslowski M, Arsiray T, Dhaene K, Praet M, Victor A et al (2006) Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer 118(10):2522-2528, Epub 2005/12/15.
38. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H et al (2010) BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 12(4):380-389, Epub 2010/03/17.
39. Yamada HY, Rao CV (2009) BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy. Int J Oncol 35(5):1101-1109, Epub 2009/09/30.
40. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (2008) Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 182(1):1-11, Epub 2008/03/11.
41. Laue K, Daujat S, Crump JG, Plaster N, Roehl HH, Kimmel CB et al (2008) The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. Development 135(11):1935-1946, Epub 2008/05/13.
42. Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C et al (2008) Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol 28(22):6828-6843, Epub 2008/09/17.
43. Kalla C, Nentwich H, Schlotter M, Mertens D, Wildenberger K, Dohner H et al (2005) Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes. Genes Chromosomes Cancer 42(2):128-143, Epub 2004/11/16.
44. Lee SK, Park EJ, Lee HS, Lee YS, Kwon J (2012) Genome-wide screen of human bromodomain- containing proteins identifies Cecr2 as a novel DNA damage response protein. Mol Cells 34(1):85-91, Epub 2012/06/16.
45. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al (2011) CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471(7337):235-239, Epub 2011/03/11.
46. Gong AY, Eischeid AN, Xiao J, Zhao J, Chen D, Wang ZY et al (2012) miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer 12(1):492, Epub 2012/10/26.
47. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF et al (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24(3):300-303, Epub 2000/03/04.
48. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ (2000) MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 28(2):138-144, Epub 2000/05/29.
49. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajduch M et al (2009) The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 15(5):1755-1761, Epub 2009/02/05.
50. Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7(11):823-833, Epub 2007/10/25.
51. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331):539-542, Epub 2011/01/21.
52. Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T et al (2008) BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 68(6):1667-1674, Epub 2008/03/15.
53. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y (1996) A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382(6589):319-324, Epub 1996/07/25.
54. Ge X, Jin Q, Zhang F, Yan T, Zhai Q (2009) PCAF acetylates {beta}-catenin and improves its stability. Mol Biol Cell 20(1):419-427, Epub 2008/11/07.
55. Armas-Pineda C, Arenas-Huertero F, Perezpenia-Diazconti M, Chico-Ponce de Leon F, Sosa-Sainz G, Lezama P et al (2007) Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors. J Exp Clin Cancer Res 26(2):269-276, Epub 2007/08/30.
56. De Semir D, Nosrati M, Bezrookove V, Dar AA, Federman S, Bienvenu G et al (2012) Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proc Natl Acad Sci USA 109(18):7067-7072, Epub 2012/04/19.
57. Tokuda E, Fujita N, Oh-hara T, Sato S, Kurata A, Katayama R et al (2007) Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, downregulates PI3K/Akt signaling and suppresses tumor growth in vivo. Cancer Res 67(20):9666-9676, Epub 2007/10/19.
58. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 98(2):629-634, Epub 2001/01/10.
59. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M et al (2012) Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 109(5):E252-E259, Epub 2012/01/12.
60. Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M et al (2011) Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene 30(29):3295-3304, Epub 2011/04/12.
61. Reisman D, Glaros S, Thompson EA (2009) The SWI/SNF complex and cancer. Oncogene 28(14):1653-1668, Epub 2009/02/24.
62. Schneppenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86(2):279-284, Epub 2010/02/09.
63. Negorev DG, Vladimirova OV, Kossenkov AV, Nikonova EV, Demarest RM, Capobianco AJ et al (2010) Sp100 as a potent tumor suppressor: accelerated senescence and rapid malignant transformation of human fibroblasts through modulation of an embryonic stem cell program. Cancer Res 70(23):9991-10001, Epub 2010/12/02.
64. Yordy JS, Moussa O, Pei H, Chaussabel D, Li R, Watson DK (2005) SP100 inhibits ETS1 activity in primary endothelial cells. Oncogene 24(5):916-931, Epub 2004/12/14.
65. Nicewonger J, Suck G, Bloch D, Swaminathan S (2004) Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression. J Virol 78(17):9412-9422, Epub 2004/08/17.
66. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R et al (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40(10):1204-1210, Epub 2008/09/02.
67. Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V et al (2011) Prognostic significance of TRIM24/TIF-1alpha gene expression in breast cancer. Am J Pathol 178(4):1461-1469, Epub 2011/03/26.
68. Li H, Sun L, Tang Z, Fu L, Xu Y, Li Z et al (2012) Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS One 7(5):e37657, Epub 2012/06/06.
69. Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M et al (2011) Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci USA 108(20):8212-8217, Epub 2011/05/03.
70. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M et al (2007) Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 39(12):1500-1506, Epub 2007/11/21.
71. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S et al (2010) TRIM24 links a noncanonical histone signature to breast cancer. Nature 468(7326):927-932, Epub 2010/12/18.
72. Yang H, Zhang C, Zhao X, Wu Q, Fu X, Yu B et al (2010) Analysis of copy number variations of BS69 in multiple types of hematological malignancies. Ann Hematol 89(10):959-964, Epub 2010/04/29.
73. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF et al (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5):523-535, Epub 2003/12/04.
74. Moriniere J, Rousseaux S, Steuerwald U, Soler-Lopez M, Curtet S, Vitte AL et al (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461(7264):664-668.
75. Vidler LR, Brown N, Knapp S, Hoelder S (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem 55(17):7346-7359, Epub 2012/07/14.
76. Zeng L, Li J, Muller M, Yan S, Mujtaba S, Pan C et al (2005) Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J Am Chem Soc 127(8):2376-2377, Epub 2005/02/24.
77. Sachchidanand, Resnick-Silverman L, Yan S, Mutjaba S, Liu WJ, Zeng L et al (2006) Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem Biol 13(1):81-90, Epub 2006/01/24.
78. Borah JC, Mujtaba S, Karakikes I, Zeng L, Muller M, Patel J et al (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 18(4):531-541, Epub 2011/04/26.
79. Demont E, Gosmini R (2011) Tetrahydroquinoline derivatives as bromodomain inhibitors. International patent WO/2011/054848. GLAXOSMITHKLINE LLC:1-199.
80. Ito T, Umehara T, Sasaki K, Nakamura Y, Nishino N, Terada T et al (2011) Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol 18(4):495-507, Epub 2011/04/26.
81. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067-1073, Epub 2010/09/28.
82. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW et al (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468(7327):1119-1123, Epub 2010/11/12.
83. Chung CW, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL et al (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem 54(11):3827-3838, Epub 2011/05/17.
84. Filippakopoulos P, Picaud S, Fedorov O, Keller M, Wrobel M, Morgenstern O et al (2012) Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem 20(6):1878-1886, Epub 2011/12/06.
85. Hewings DS, Wang M, Philpott M, Fedorov O, Uttarkar S, Filippakopoulos P et al (2011) 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54(19):6761-6770, Epub 2011/08/20.
86. Bamborough P, Diallo H, Goodacre JD, Gordon L, Lewis A, Seal JT et al (2012) Fragmentbased discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J Med Chem 55(2):587-596, Epub 2011/12/06.
87. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA (2003) BRD4- NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63(2):304-307, Epub 2003/01/25.
88. French CA (2010) Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol 63(6):492-496, Epub 2008/06/17.
89. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD et al (2000) Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92(16):1355-1357, Epub 2000/08/17.
90. Iyer NG, Ozdag H, Caldas C (2004) p300/CBP and cancer. Oncogene 23(24):4225-4231, Epub 2004/05/25.
91. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS et al (1996) The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14(1):33-41, Epub 1996/09/01.
92. Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billstrom R, Strombeck B et al (2001) Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16) (q22;p13). Hum Mol Genet 10(4):395-404, Epub 2001/02/07.
93. Lai JL, Jouet JP, Bauters F, Deminatti M (1985) Chronic myelogenous leukemia with translocation (8;22): report of a new case. Cancer Genet Cytogenet 17(4):365-366, Epub 1985/08/01.
94. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N et al (2001) Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22) (p11;q13) chromosome translocation. Leukemia 15(1):89-94, Epub 2001/03/13.
95. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S et al (1997) All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90(2):535-541.
96. Satake N, Ishida Y, Otoh Y, Hinohara S, Kobayashi H, Sakashita A et al (1997) Novel MLLCBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16) (q23;p13) chromosome translocation. Genes Chromosomes Cancer 20(1):60-63, Epub 1997/09/18.
97. Giles RH, Petrij F, Dauwerse HG, den Hollander AI, Lushnikova T, van Ommen GJ et al (1997) Construction of a 1.2-Mb contig surrounding, and molecular analysis of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3. Genomics 42(1):96-114.
98. Quintas-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J et al (2012) Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 118(21):5283-5292, Epub 2012/04/21.
99. Ding WM, Yang L, Zheng Y, Sun HY, Liang H, Wang JJ (2012) Preparation of anti-BRDTNY polyclonal antibody and expression of BRDT-NY protein in digestive tract tumors. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28(8):847-850, Epub 2012/08/07.
100. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J et al (2002) Gene expression patterns in human liver cancers. Mol Biol Cell 13(6):1929-1939, Epub 2002/06/12.
101. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503-511, Epub 2000/02/17.
102. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530-536, Epub 2002/02/02.
103. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100(10):5974-5979, Epub 2003/04/26.
104. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V et al (2010) Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 29(37):5171-5181, Epub 2010/06/29.
105. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F et al (2009) ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res 69(21):8491-8498, Epub 2009/10/22.
106. Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K et al (2000) BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 60(21):6171-6177, Epub 2000/11/21.
107. Muchardt C, Yaniv M (2001) When the SWI/SNF complex remodels...the cell cycle. Oncogene 20(24):3067-3075, Epub 2001/06/23.
108. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J et al (2008) Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29(5):617-622, Epub 2008/04/05.
109. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV (1999) c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22(1):102-105, Epub 1999/05/13.
110. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE (2003) Loss of BRG1/ BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63(3):560-566, Epub 2003/02/05.
111. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE (2001) Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 186(1):136-145, Epub 2001/01/09.
112. Hill DA, Chiosea S, Jamaluddin S, Roy K, Fischer AH, Boyd DD et al (2004) Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme. J Cell Sci 117(Pt 24):5847-5854, Epub 2004/11/13.
113. Becker TM, Haferkamp S, Dijkstra MK, Scurr LL, Frausto M, Diefenbach E et al (2009) The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Mol Cancer 8:4, Epub 2009/01/20